Visceral Pain Market Size and Forecast

Your CatalystTo a Lucrative Business
Visceral Pain Market Share, Size, Analysis, Growth, Industry
Trends and Forecasts to 2024 | Hexa Research
“The global visceral pain market size was estimated at
USD 9.51 billion in 2016 and is expected to witness
substantial growth on account of its increasing
prevalence.”
The global Visceral Pain Market is expected to reach USD 14.22 billion by 2024, driven by the increasing
geriatric population globally. Increasing prevalence of visceral pain and rising awareness regarding the same is
projected to drive market growth over the forecast period.
In 2016, North America held the majority of share in global visceral pain market owing to the increasing
healthcare expenditure. Additionally, the high prevalence of Crohn’s and irritable bowel is expected to propel
the growth of the market over the projected period.
Asia Pacific is expected to be the fastest growing region with the CAGR of 6.2%. The increase in the healthcare
infrastructure and presence of a large pool of patients is projected to drive the demand for the visceral pain
industry during the forecast period.
Analgesic segment dominated the market for the visceral pain with the market share of 60.4%. The major share
of the analgesic segment is attributed to the increasing penetration of generic drug. Furthermor e, rising
healthcare expenditure and an increasing use of opioids for the chronic pain are the key factors attributing to
its share.
Browse Details of Report @ https://www.hexaresearch.com/research-report/visceral-pain-market
Follow Us:
Your CatalystTo a Lucrative Business
In 2016, Crohn’s disease was the largest indication segment for the visceral pain market contributing to 41.4%
of the market share. Increasing occurrences of Crohn’s disease across the globe coupled with the growing drug
therapies for the treatment of the disease are the key factors attributing to the major share. Furthermore,
increasing awareness about Crohn’s disease is fueling the demand for treatment therapies.
Key market players include Pfizer, Johnson & Johnson, Abbvie, Takeda, Allergan, and AstraZeneca. These
companies are focusing on R&D for visceral pain therapeutics. These companies are likely to cater their
products to patients affected by visceral pain. The growth of the geriatric population is expected to help in
augmenting the profits of these companies over the next few years.
Growing focus on research and development by pharmaceutical companies and government initiatives are
expected to boost the visceral pain industry during the forecast period. The market is projected to witness
significant gain during the forecast period owing to increasing collaboration within pharmaceutical companies.
Also, factors such as increasing awareness among people regarding visceral pain are further anticipated to
propel the market growth.
Hexa Research has segmented the global visceral pain market on the basis of therapeutics, indications and
region:
Segmentation by therapeutics, 2014 - 2024 (USD Million)
• Analgesics
• Narcotics
• NSAID
• Pain modifiers
• Tricyclic Antidepressants
• Tricyclic Anticonvulsant
• Others
Segmentation by indications, 2014 - 2024 (USD Million)
• Interstitial cystitis
• Crohn’s
• Irritable bowel
• Chronic prostatitis
Segmentation by region, 2014 - 2024 (USD Million)
• North America
• Europe
• Asia Pacific
• Rest of the World (RoW)
Key players analyzed:
• Pfizer Inc.
• Allergan
• Johnson & Johnson
• Bayer AG
• Takeda Pharmaceutical Company Limited
Follow Us:
Your CatalystTo a Lucrative Business
• Mallinkrodt Pharmaceuticals
• AbbVie Inc.
• AstraZeneca
Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/clinicaldiagnostics-industry
Follow Us:
Your CatalystTo a Lucrative Business
Table of Content of Visceral Pain Market
Chapter 1. Market Summary
1.1. Market trends & movement
Chapter 2. Visceral Pain Market Trends: Drivers & Opportunities
2.1. Introduction
2.2. Key industry trends
2.3. Market drivers
2.4. Market restraints
2.5. Value chain analysis
2.6. Porter's Five Forces analysis
2.7. SWOT
2.8. Regulatory framework
Chapter 3. Visceral Pain Market Trends, By Therapeutics
3.1. Global visceral pain market movement, by therapeutics, 2014 & 2024
3.2. Analgesic
3.2.1. Market estimates and forecast, 2014 – 2024 (USD Million)
3.2.2. Market estimates and forecast, by product, 2014 – 2024 (USD Million)
3.2.2.1. Narcotics
3.2.2.1.1. Market estimates and forecast, 2014 – 2024 (USD Million)
3.2.2.2. NSAID
3.2.2.2.1. Market estimates and forecast, 2014 – 2024 (USD Million)
3.3. Pain Modifiers
3.3.1. Market estimates and forecast, 2014 – 2024 (USD Million)
3.3.2. Market estimates and forecast, by product, 2014 – 2024 (USD Million)
3.3.2.1. Tricyclic Antidepressants
3.3.2.1.1. Market estimates and forecast, 2014 – 2024 (USD Million)
3.3.2.2. Tricyclic Anticonvulsant
3.3.2.2.1. Market estimates and forecast, 2014 – 2024 (USD Million)
3.4. Others
3.4.1. Market estimates and forecast, 2014 – 2024 (USD Million)
Follow Us:
Your CatalystTo a Lucrative Business
Chapter 4. Visceral pain Market Trends, By indications
4.1. Global visceral pain market movement, by indications, 2014-2024
4.2. Interstitial cystitis
4.2.1. Market estimates and forecast, 2014 – 2024 (USD Million)
4.3. Crohn’s
4.3.1. Market estimates and forecast, 2014 – 2024 (USD Million)
4.4. Irritable bowel
4.4.1. Market estimates and forecast, 2014 – 2024 (USD Million)
4.5. Chronic prostatitis
4.5.1. Market estimates and forecast, 2014 – 2024 (USD Million)
Chapter 5. Visceral pain Market Trends, By Region
5.1. Global visceral pain market movement, by region, 2014 & 2024
5.1.1. North America
5.1.1.1. Market estimates and forecast, 2014 – 2024 (USD Million)
5.1.1.2. Market estimates and forecast, by therapeutic class, 2014 – 2024 (USD Million)
5.1.1.2.1. Market estimates and forecast, by analgesics, 2014 – 2024 (USD Million)
5.1.1.2.2. Market estimates and forecast, by pain modifiers, 2014 – 2024 (USD Million)
5.1.1.3. Market estimates and forecast, by indications, 2014 – 2024 (USD Million)
5.1.2. Europe
5.1.2.1. Market estimates and forecast, 2014 – 2024 (USD Million)
5.1.2.2. Market estimates and forecast, by therapeutic class, 2014 – 2024 (USD Million)
5.1.2.2.1. Market estimates and forecast, by analgesics, 2014 – 2024 (USD Million)
5.1.2.2.2. Market estimates and forecast, by pain modifiers, 2014 – 2024 (USD Million)
5.1.2.3. Market estimates and forecast, by indications, 2014 – 2024 (USD Million)
5.1.3. Asia Pacific
5.1.3.1. Market estimates and forecast, 2014 – 2024 (USD Million)
5.1.3.2. Market estimates and forecast, by therapeutic class, 2014 – 2024 (USD Million)
5.1.3.2.1. Market estimates and forecast, by analgesics, 2014 – 2024 (USD Million)
5.1.3.2.2. Market estimates and forecast, by pain modifiers, 2014 – 2024 (USD Million)
5.1.3.3. Market estimates and forecast, by indications, 2014 – 2024 (USD Million)
5.1.4. RoW
5.1.4.1. Market estimates and forecast, 2014 – 2024 (USD Million)
5.1.4.2. Market estimates and forecast, by therapeutic class, 2014 – 2024 (USD Million)
5.1.4.2.1. Market estimates and forecast, by analgesics, 2014 – 2024 (USD Million)
Follow Us:
Your CatalystTo a Lucrative Business
5.1.4.2.2. Market estimates and forecast, by pain modifiers, 2014 – 2024 (USD Million)
5.1.4.3. Market estimates and forecast, by indications, 2014 – 2024 (USD Million)
Chapter 6. Competitive Landscape
6.1. Competitive landscape analysis, 2016
6.2. Strategic framework
6.3. Potential customer base concentration
6.4. Company market positioning
6.5. Company profiles
6.5.1. Pfizer Inc.
6.5.1.1. Company Overview
6.5.1.2. Product Benchmarking
6.5.1.3. Financial Performance
6.5.1.4. Recent Initiatives
6.5.2. Allergan
6.5.2.1. Company Overview
6.5.2.2. Product Benchmarking
6.5.2.3. Financial Performance
6.5.2.4. Recent Initiatives
6.5.3. Johnson & Johnson
6.5.3.1. Company Overview
6.5.3.2. Product Benchmarking
6.5.3.3. Financial Performance
6.5.3.4. Recent Initiatives
6.5.4. Bayer AG
6.5.4.1. Company Overview
6.5.4.2. Product Benchmarking
6.5.4.3. Financial Performance
6.5.4.4. Recent Initiatives
6.5.5. Takeda Pharmaceutical Company Limited
6.5.5.1. Company Overview
6.5.5.2. Product Benchmarking
6.5.5.3. Financial Performance
6.5.5.4. Recent Initiatives
6.5.6. Mallinkrodt Pharmaceuticals
6.5.6.1. Company Overview
Follow Us:
Your CatalystTo a Lucrative Business
6.5.6.2. Product Benchmarking
6.5.6.3. Financial Performance
6.5.6.4. Recent Initiatives
6.5.7. AbbVie Inc.
6.5.7.1. Company Overview
6.5.7.2. Product Benchmarking
6.5.7.3. Financial Performance
6.5.7.4. Recent Initiatives
6.5.8. AstraZeneca
6.5.8.1. Company Overview
6.5.8.2. Product Benchmarking
6.5.8.3. Financial Performance
6.5.8.4. Recent Initiatives
6.5.9. List of other vendors
Chapter 7. Methodology and Scope
7.1. Research methodology
7.2. Research Scope & Assumptions
7.3. List of data sources
Follow Us:
Your CatalystTo a Lucrative Business
About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research
and consulting services to a host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients obtain clarity about their business
environment and enable them to undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - https://www.hexaresearch.com
Follow Us:

The global geriatric population is anticipated to cross 2 billion by 2050, and this will act as a key factor for the expansion of the visceral pain market worldwide.

Download Report